Delving into the Latest Updates on Testosterone with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

17beta-hydroxy-4-androsten-3-one, 4-androsten-17β-ol-3-one, Testosterone (JAN/USP)

+ [34]

Target

AR

Action

agonists

Mechanism

AR agonists(Androgen Receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Low testosterone levelsTestosterone deficiencyHypogonadism

Inactive Indication

Alzheimer DiseaseAndrogen deficiencyArthralgia+ [39]

Originator Organization

AbbVie, Inc.

Active Organization

Qinhuangdao Zizhu Pharmaceutical Co. Ltd.Besins Healthcare (UK) Ltd.

Acerus Pharmaceuticals Corp.

+ [4]

Inactive Organization

Teva NI Ltd.

Eli Lilly & Co.

University of Washington

+ [26]

License Organization

Actient Pharmaceuticals LLCAmneal Intermediate, Inc.Lunatus SL

+ [15]

Drug Highest PhaseApproved

First Approval Date

United States (29 Sep 1995),

Hypogonadism

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC19H28O2

InChIKeyMUMGGOZAMZWBJJ-DYKIIFRCSA-N

CAS Registry58-22-0

Hypoactive sexual desire disorder (HSDD) is described as the most common form of female sexual dysfunction, particularly affecting peri- and postmenopausal women and is associated with significant distress and reduced quality of life. The TESTA-MIND study will evaluate the efficacy and safety of a standardized compounded transdermal testosterone gel in a randomized, double-blind, placebo-controlled design to address the lack of FDA-approved options and limited high-quality evidence for treating decreased libido in women.

Start Date01 Apr 2026

Sponsor / Collaborator

The University of Texas Health Science Center at Houston

NCT07500766

/ Not yet recruitingPhase 2IIT

Clinical Evaluation of Subcutaneous Testosterone Implants in Men With Symptomatic Hypogonadism

Introduction:
Male hypogonadism is a clinical syndrome associated with significant consequences for health and quality of life. In Brazil, approved testosterone replacement therapy options are limited to injectable formulations and transdermal gels, which are often associated with suboptimal adherence. Subcutaneous testosterone implants, already used in the United States and recommended by international guidelines, represent a promising alternative but are not yet available in Brazil.
Objective:
To evaluate the efficacy, safety, pharmacokinetics, and quality-of-life impact of 200 mg testosterone implants manufactured in Brazil for the treatment of men with symptomatic hypogonadism.
Methods:
This is a prospective interventional study conducted at the Division of Urology of the Hospital das Clínicas, University of São Paulo School of Medicine (FMUSP). Thirty cisgender hypogonadal men meeting strict inclusion and exclusion criteria will be enrolled. Participants will receive subcutaneous testosterone implants totaling 800 mg and will be followed for six months. Serial blood sampling will be performed to assess hormonal levels (total and free testosterone, LH, FSH, and PSA) and metabolic parameters (lipid profile, body mass index, and waist circumference). Validated questionnaires, including the IIEF-15, ADAM, and WHOQOL-BREF, will be used to evaluate sexual function, hypogonadal symptoms, quality of life, and patient satisfaction.
Outcomes:
The primary outcome is the ability of the implants to achieve and maintain therapeutic serum testosterone levels (450-800 ng/dL). Secondary outcomes include pharmacokinetic profile (Cmax, half-life, and mean duration), metabolic effects, changes in quality of life, and treatment adherence.
Clinical Significance:
This study advances the understanding of a testosterone replacement modality that may offer greater convenience for selected patients and for which data on nationally manufactured products are currently lacking. Over a six-month period, the study will investigate laboratory behavior, clinical impact, and patient satisfaction.
Relevance and Impact:
This is the first study of its kind conducted in Brazil, combining methodological rigor with a robust design to evaluate the safety and efficacy of domestically manufactured testosterone implants. The methodology incorporates detailed ethical and scientific criteria, ensuring high-quality data. The results may support regulatory and clinical decision-making, benefiting patients and potentially contributing to the Brazilian Unified Health System (SUS).

Start Date01 Mar 2026

Sponsor / Collaborator

University of Sao Paulo

NCT07143279

/ RecruitingEarly Phase 1IIT

Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life

This is a monocentric, single-arm prospective pilot study that will enrol hypogonadal (testosterone < 231 ng/dL) male subjects in best supportive care, with no further therapeutic options and no need for resuscitation.
Currently, testosterone formulations for intramuscular (IM) injection and subcutaneous injection as well as for oral and transdermal administration have been approved for androgen therapy. To date, injectable testosterone is the most commonly used formulation. To increase serum testosterone levels to the physiological range IM injections of testosterone every 2-3 weeks are required, which lead to supraphysiological peaks shortly after administration, followed by a sharp fall in levels thereafter. Testosterone levels before the next injection are frequently in the hypogonadal range. For this reason, Sustanon 250® (1 ml, IM) will be administered on day 0 after confirmation of hypogonadism by blood test and then every 15 days in this trial given the limited life expectancy of the subjects and to maximise the effect and benefit of testosterone supplementation.
The Edmonton questionnaire and ADL questionnaire will be completed before the injection on day 0 and then every 15 days at the time of injection until subject's death or if a subject is discontinued from the study treatment/procedures for any other reasons than death. In parallel, the EQ-5D-3L questionnaire will be completed by a family member or a proxy.

Start Date11 Feb 2026

Sponsor / Collaborator

Jules Bordet Institute

100 Clinical Results associated with Testosterone

Login to view more data

100 Translational Medicine associated with Testosterone

Login to view more data

100 Patents (Medical) associated with Testosterone

Login to view more data

88,708

Literatures (Medical) associated with Testosterone

31 Dec 2026·ANNALS OF HUMAN BIOLOGY

The challenges of optimising the treatment of children diagnosed with idiopathic short stature

Article

Author: Romero, Christopher J. ; Rapaport, Robert

Physicians who treat children with idiopathic short stature (ISS) are challenged in deciding whether the intervention to improve final height is truly efficacious, given the heterogeneity of the diagnosis of ISS. There are numerous studies and reviews that have attempted to assess and demonstrate the benefit of various interventions, such as growth hormone therapy and aromatase inhibitors. Recently, Zhang et al. published a well-written meta-analysis entitled "Comparative effects of growth hormone, testosterone, and aromatase inhibitors on height gain in children and adolescents with idiopathic short statures: a network meta-analysis," attempting to stratify the benefit of several interventions. Our commentary seeks to highlight the importance of more research needed in this field and the complexities of treating children with ISS.

31 Dec 2026·Aging Male

Vitamin D levels in relation to sexual steroids, sexual function, and quality of life in patients of an andrology outpatient clinic

Article

Author: Haider, Karim Sultan ; Zitzmann, Michael

OBJECTIVE:

This study sought to delineate a putative synergistic interplay between vitamin D and testosterone and their conjoint associations with sexual function and quality of life in men presenting with symptoms of hypogonadism.

METHODS:

A retrospective cohort analysis was performed in men attending the andrological clinic of the University Hospital Münster (Germany) between 2016 and 2021. Individuals exhibited complete biochemical, clinical, and questionnaire datasets. Endocrine parameters, validated psychometric instruments, and demographic variables were systematically evaluated.

RESULTS:

Among 5,324 screened men, 2,059 fulfilled inclusion criteria (mean age 43.9 years). The cohort displayed a pronounced symptom burden (mitigated wellbeing and erectile function). 25-hydroxyvitamin D and testosterone concentrations resided predominantly within suboptimal ranges. Both vitamin D and testosterone correlated inversely with BMI and AMS scores, and positively with IIEF-EF scores (all p < 0.001). Effect size analyses and multiples regressions indicated a robust dependency of symptom severity on vitamin D as well as testosterone status across somatic, sexual, and metabolic indices, underscoring an interdependent relationship between vitamin D and testosterone in shaping sexual function and well-being.

CONCLUSION:

Albeit causality cannot be inferred, this analysis highlights a clinical convergence of vitamin D and testosterone in modulating sexual health and quality of life in men.

31 Dec 2026·Aging Male

Association between chronic inflammation status and serum testosterone and free testosterone in adult males

Article

Author: Jiao, Yong-zheng ; Meng, Yu-hang ; Qi, Shuai-dang ; Su, Liang ; Wu, Jie ; Zhang, Si-zheng

BACKGROUND:

Chronic inflammation may contribute to biochemical hypogonadism, but evidence regarding composite inflammatory indicators is limited. This study examined the associations of the systemic inflammation response index (SIRI) and aggregate index of systemic inflammation (AISI) with serum testosterone and free testosterone (FT) in adult males.

METHODS:

Data were obtained from NHANES 2011-2016 and 2021-2023, including 7,576 men for serum testosterone and 3,590 for FT. Multivariable regression, smoothing curves, threshold effect, and age-stratified analyses were conducted.

RESULTS:

Higher SIRI and AISI were significantly associated with lower serum testosterone and FT levels (P < 0.0001). Testosterone levels were lowest in the highest quartiles of SIRI and AISI. Nonlinear inverse associations with serum testosterone were observed for both indices, and AISI also showed a nonlinear association with FT, while SIRI showed a linear inverse association. A positive association with biochemical hypogonadism was observed only when defined by serum testosterone. The inverse associations were consistent across all ages for serum testosterone but were evident for FT only in men aged 20-39 and ≥60 years.

CONCLUSION:

SIRI and AISI are independently associated with lower serum testosterone in men, while associations with FT appear age-dependent.

221

News (Medical) associated with Testosterone

31 Mar 2026

·www.einpresswire.com

Testosteronology Society™ Strengthens Clinician Collaboration Through Twice-Weekly Live Grand Rounds

Twice-weekly Grand Rounds enable clinicians to present complex cases live within a multidisciplinary consortium of hormone therapy specialists. FORT LAUDERDALE, FL, UNITED STATES, March 31, 2026 / EINPresswire.com / -- The Testosteronology Society™ is strengthening clinician collaboration through twice-weekly live Grand Rounds, a recurring case-based forum that gives members the opportunity to present difficult testosterone, androgen, and hormone therapy cases for multidisciplinary review and discussion. The program is designed to help clinicians make more informed decisions in challenging situations and improve the care delivered to their patients. Grand Rounds addresses a practical need in hormone-related medicine. Many clinicians encounter patients whose symptoms, lab findings, treatment responses, medication profiles, comorbidities, and mental health variables do not fit neatly into simple treatment frameworks. In these situations, isolated decision-making can lead to uncertainty and inconsistency. The Testosteronology Society™ created Grand Rounds to give members a structured environment where they can bring cases forward, hear different perspectives, and benefit from the shared clinical experience of a diverse professional community. The Society’s Grand Rounds brings together a wide range of medical disciplines that contribute to better testosterone, androgen, and hormone-related care. These include internal medicine, family medicine, naturopathic medicine, functional medicine, pharmacology, women’s health and menopausal medicine, cardiology, infectious disease, emergency medicine, endocrinology, urology, and psychiatry. This multidisciplinary structure is a defining strength of the program because difficult cases often require more than a single-specialty perspective. These twice-weekly sessions are conducted as live Zoom meetings where clinicians from across the United States and internationally can present cases and collaborate in real time across multiple medical disciplines. By creating a place where these perspectives can intersect regularly, the Testosteronology Society™ is helping members think more clearly and act more carefully in the best interest of their patients. Grand Rounds allows clinicians to test clinical reasoning, identify blind spots, compare approaches, and better understand the tradeoffs that shape hormone-related care. The result is stronger education for the clinician and better-informed care for the patient. Thomas O’Connor, M.D., Founder and CEO of the Testosteronology Society™, said the organization was built around the idea that higher standards in hormone care require deeper collaboration across disciplines. “I wanted the Testosteronology Society™ to be the world’s first diverse consortium of healthcare professionals dedicated to providing the highest standard of care for people receiving testosterone, androgens, and other hormone therapies,” said Dr. O’Connor. “This work is bigger than any one doctor or healthcare professional and bigger than any single specialty. It takes multiple disciplines to properly care for people on testosterone, androgens, and hormones.” Testosteronology ® is the clinical foundation of the Testosteronology Society™. It is the Society’s defining medical framework for understanding testosterone, androgens, and hormone-related care through deeper physiology, broader clinical context, and more disciplined reasoning rather than oversimplified treatment models. That foundation supports the Society’s emphasis on multidisciplinary collaboration, careful risk evaluation, individualized care, and a higher standard of decision-making for complex patient presentations. For Society members, the value of Grand Rounds extends beyond the live sessions. The meetings are also recorded, organized, and made searchable as part of the Society’s growing educational resources. This creates an expanding case experience library that members can review as they encounter similar clinical problems in practice. This growing archive adds practical value to the Society’s clinician community and educational mission. It helps members learn not only from their own cases, but also from the collective experience of the Society. When a clinician faces a challenge that is difficult to solve alone, the searchable Grand Rounds archive can provide relevant patterns, decision frameworks, and multidisciplinary insight that support better next steps. “Being part of Testosteronology Grand Rounds has transformed how I approach TRT,” said Stephanie Tobiasz. “The opportunity to discuss complex cases with expert practitioners across a wide range of medical disciplines, share evidence-based protocols, and apply harm-reduction strategies has meaningfully strengthened my practice and the care I provide to patients.” “Attending Testosteronology Grand Rounds equips me with the opportunity to increase my knowledge base and connect with other like-minded healthcare providers who strive to provide the highest standard of care to their patients,” said Jason Bennett, APRN, PMHNP-BC. Steve Sunshine, Chief Operating Officer of the Testosteronology Society™, said the Society views Grand Rounds as an important part of helping clinicians avoid practicing in isolation. “The biggest value of Grand Rounds is that clinicians do not have to work through difficult cases on their own,” said Sunshine. “Our members can present complex cases live in a twice-weekly collaborative setting, hear input from multiple medical disciplines, and continue learning from a growing searchable archive of prior meetings. That combination helps clinicians deliver stronger care and helps patients benefit from broader clinical experience than any one provider could develop alone.” Through twice-weekly live collaboration and a growing recorded case archive, the Testosteronology Society™ continues to build a stronger educational and clinical support system for the medical specialty of Testosteronology ® . About The Testosteronology Society™ The Testosteronology Society™ is a multidisciplinary consortium of healthcare professionals dedicated to advancing the highest standard of care for people receiving testosterone, androgens, and other hormone therapies. Through clinician education, peer collaboration, and twice-weekly Grand Rounds, the Society supports stronger clinical reasoning and improved readiness for complex patient care in the medical specialty of Testosteronology ® . Steve Sunshine Testosteronology Society™ +1 561-441-3642 sunshine@testosteronology.com Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

31 Mar 2026

·www.drugs.com

Intermittent Fasting Might Help Manage Female Hormone Imbalance, Trial Shows

TUESDAY, March 31, 2026 — Intermittent fasting might help manage symptoms from a hormonal condition that affects nearly 1 in 5 women, new clinical trial results say. Weight loss associated with intermittent fasting helped lower testosterone levels in women with polycystic ovary syndrome (PCOS), researchers reported March 27 in the journal Nature Medicine . These lowered levels could wind up improving PCOS symptoms over time, researchers said. “This study and several other studies published by our lab and others show that intermittent fasting can actually improve female hormone levels, particularly in women with PCOS,” researcher Krista Varady , a professor of nutrition at the University of Illinois-Chicago, said in a news release. PCOS occurs when women don’t create enough female hormones needed to ovulate, according to Johns Hopkins Medicine. As a result, the ovaries develop many small fluid-filled sacs called cysts, which produce male hormones like testosterone. Higher levels of these male hormones cause problems like irregular periods, weight gain and infertility among women with PCOS, Johns Hopkins says. “We’re looking for other ways of lowering testosterone levels in these women,” Varady said. “One way is through weight loss. If someone loses around 5% of their body weight, they can actually help lower testosterone levels and sidestep any kind of drug intervention.” Intermittent fasting — restricting eating to a six-to-eight hour daily window — is one potential means of weight loss, but some critics have said the diet might instead disrupt female hormones. “There’s a particular sentiment that intermittent fasting is really bad for women,” Varady said. For the trial, researchers recruited 76 women with PCOS and assigned them to one of three groups. One group adopted intermittent fasting; another tried to lose weight through calorie counting; and the third served as a control group that continued their usual diet. Both fasting and calorie counting cut the women’s food intake by about 200 calories a day, and both groups lost an average 10 pounds during the six-month trial. Both dieting groups also had a decrease in their testosterone levels, researchers said. But only intermittent fasting reduced free androgen index, the ratio between testosterone and the protein that transports it through blood, researchers said. This is a marker of how much active testosterone is reaching a body’s tissues. Intermittent fasting didn’t lessen PCOS symptoms like irregular periods, but researchers said those symptoms might improve with longer time on the diet. About 80% of the women assigned to intermittent fasting said they planned to continue the eating pattern, Varady said. Sources University of Illinois-Chicago, news release, March 27, 2026

24 Mar 2026

·www.drugs.com

Testosterone Affects Adipose Distribution in Older Women After Hip Fracture

TUESDAY, March 24, 2026 -- For older women recovering from hip fracture, testosterone does not decrease overall adipose stores but does have a favorable effect on relative visceral adiposity, according to a study published in the March issue of Obesity Pillars . Jacob E. Earp, Ph.D., from the University of Connecticut in Storrs, and colleagues examined the effects of testosterone therapy on total adipose tissue (TAT) and adipose distribution in older women recovering from a hip fracture. Participants were assigned to a six-month exercise intervention combined with topical testosterone gel (EX + T; 35 participants) or placebo gel (EX + P; 31 participants). The researchers found that the changes in TAT, appendicular adipose tissue (AAT), percentage AAT, and visceral adipose tissue (VAT) were similar during the intervention. Favorable effects of testosterone were seen on relative visceral adiposity, with relative changes in percentage VAT from preintervention (Δ3.51 ± 18.42 versus −Δ10.57 ± 17.13 percent for EX + P versus EX + T). "If you have injury and just generally as we age, we expect an increase in visceral fat," Earp said in a statement. "This really bucked that trend and caused selective reduction of fat in that visceral compartment." Abstract/Full Text

Clinical Result

100 Deals associated with Testosterone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00075	Testosterone	G03BA03	DB00624

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
secondary testicular failure	United States	Endo Operations Ltd.	29 Dec 2010
Sexual Dysfunctions, Psychological	European Union	Warner Chilcott Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	European Union	Teva NI Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	Iceland	Warner Chilcott Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	Iceland	Teva NI Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	Liechtenstein	Teva NI Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	Liechtenstein	Warner Chilcott Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	Norway	Warner Chilcott Ltd.	28 Jul 2006
Sexual Dysfunctions, Psychological	Norway	Teva NI Ltd.	28 Jul 2006
Low testosterone levels	United States	Endo Operations Ltd.	31 Oct 2002
Testosterone deficiency	Australia	Teva Pharmaceuticals Australia Pty Ltd	10 Apr 2002
Hypogonadism	United States	AbbVie, Inc.	29 Sep 1995

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Klinefelter Syndrome	Phase 3	United States	Amneal Pharmaceuticals, Inc.	01 Mar 2014
Arthralgia	Phase 3	United States	Alliance Foundation Trials LLC	10 Sep 2013
Breast Cancer	Phase 3	United States	Alliance Foundation Trials LLC	10 Sep 2013
Hot Flashes	Phase 3	United States	Alliance Foundation Trials LLC	10 Sep 2013
Musculoskeletal Abnormalities	Phase 3	United States	Alliance Foundation Trials LLC	10 Sep 2013
Alzheimer Disease	Phase 3	United States	Solvay Pharmaceuticals, Inc.	01 Jul 2009
Mild cognitive disorder	Phase 3	United States	Solvay Pharmaceuticals, Inc.	01 Jul 2009
Eunuchism	Phase 3	-	Endo Pharmaceuticals, Inc.	01 Aug 2007
Multiple Endocrine Neoplasia	Phase 3	-	Abbott Laboratories	01 Feb 2007
Coronary Artery Disease	Phase 3	United States	Abbott Laboratories	01 Jan 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02938923 (STEP-HI, Pubmed \| Obes Pillars)	Phase 2	Obesity	66	Exercise + Topical Testosterone Gel	lclrefhzvr(cgavrduljg) = nzmgixtokp untwchpmej (lmaxbczjfb ) View more	Positive	01 Mar 2026
				Exercise + Placebo Gel	lclrefhzvr(cgavrduljg) = oofjlfibtg untwchpmej (lmaxbczjfb ) View more
NCT03887936 (CTgov)	Phase 4	Hypogonadism \| Diabetes Mellitus, Type 2	92	Testosterone gel 1.62% (Testosterone Arm)	zlcapqcgjw(ummxdslsng) = tyzabapupt ndcmyrbkgc (mfywxgdele, 8.7) View more	-	23 Dec 2025
				Placebo (Placebo Arm)	zlcapqcgjw(ummxdslsng) = svoetdaozq ndcmyrbkgc (mfywxgdele, 11.6) View more
NCT06154200 (CTgov)	Phase 2	Sjogren's Syndrome \| Dry Eye Syndromes \| Meibomian Gland Dysfunction	24	Vehicle gel (Vehicle Gel)	biaoqnqvvt(sxdhmetwwo) = qwkgpwhuik efjcnllhsx (zgjmnumzok, 1.2) View more	-	25 May 2025
				Testosterone gel 4.5% (Testosterone Gel 4.5%)	biaoqnqvvt(sxdhmetwwo) = avakznybnm efjcnllhsx (zgjmnumzok, 1.3) View more
NCT02938923 (STEP-HI, Pubmed \| JAMA Netw Open)	Phase 3	Hip Fractures	129	Exercise plus Topical Testosterone Gel	smrnqdrxku(pibdqsqbzt) = xmkcbmdmpp jbhrjkoycb (boadtmthmr, 8.2)	Negative	15 May 2025
				Exercise plus Placebo Gel	smrnqdrxku(pibdqsqbzt) = cbbkbelxid jbhrjkoycb (boadtmthmr, 8.4)
NCT04456296 (CTgov)	Phase 4	secondary testicular failure \| Eunuchism	673	AVEED (AVEED® (Testosterone Undecanoate Injection))	igytihtjlb(crftevfqam) = dtpcbjvywz xwvngozyjd (mqcyszrluf, zmvieyjihl - gmscsuximk) View more	-	14 Mar 2025
				FORTESTA (FORTESTA® (Testosterone Gel))	igytihtjlb(crftevfqam) = mzlvvdcqam xwvngozyjd (mqcyszrluf, psypiymzho - krfytnbkau) View more
NCT02432261 (CTgov)	Phase 1	-	44	Nestorone® /testosterone gel (Group 1)	laqgvhhfsc = kvwejmboof mtqqcjtwis (qhubkadyvg, hksvcygezj - dxcvclvoej) View more	-	13 Feb 2025
				Testosterone only gel (Group 2)	laqgvhhfsc = uypaqopvqf mtqqcjtwis (qhubkadyvg, xodokuirfo - tadipimewx) View more
NCT02938923 (STEP-HI, CTgov)	Phase 3	Hip Fractures \| Femoral Neck Fractures \| Sarcopenia	129	Testosterone+Supervised exercise training (Exercise + Testosterone (EX + T))	essekcbxia(tukpleorjs) = bjskbcnkqt edxupiydwt (grtxvqwqfs, kppraswopl - rpdznffwdu) View more	-	04 Feb 2025
				Supervised exercise training (Exercise + Placebo (EX + P))	essekcbxia(tukpleorjs) = pgxcsxeahx edxupiydwt (grtxvqwqfs, xyiivtcdhk - gkrxcicetp) View more
NCT03518034 (TRAVERSE, CTgov)	Phase 4	Hypogonadism \| Cardiovascular Diseases	5,246	AndroGel® (AndroGel 1.62%)	pugdapdlbg = ewmopimltw vnghahkxgp (jdpihfnydm, zoiilznead - mxfomriord) View more	-	13 Mar 2024
				Placebo (Placebo)	pugdapdlbg = becpewvmin vnghahkxgp (jdpihfnydm, mryaxqeqlw - sciipzewvh) View more
NCT00467987 (CTgov)	Not Applicable	Diabetes Mellitus, Type 2 \| secondary testicular failure \| Atherosclerosis	47	androgel (Androgel)	cafmlgpkdf(lmxvmmlxhb) = jhrainotdo ytgmgdppki (tvmuajneqd, 0.115) View more	-	06 Feb 2024
				placebo (Placebo)	cafmlgpkdf(lmxvmmlxhb) = khznaxbqpk ytgmgdppki (tvmuajneqd, 0.127) View more
NCT03518034 (TRAVERSE, Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 4	Hypogonadism	5,204	Testosterone gel	efyckezczz(tqlpoatjvm) = quxbdflens azhvwsvosn (iiblqctmnd )	Negative	18 Jan 2024
				Placebo gel	efyckezczz(tqlpoatjvm) = huyewzwnfj azhvwsvosn (iiblqctmnd )